Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is 3.56% as of the fiscal period ended Saturday, December 31, 2022.
Limited history available
CURX EBITDA Margin has fewer than three reported periods, so a trend chart would be misleading.
EBITDA MARGIN
3.56%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.24M
EBITDA Margin
3.56%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.28M
EBITDA Margin
-2068.24%
TTM Avg
-1510.83%
3Y Avg
-1474.78%
5Y Avg
-1474.78%
Market Cap
$7.20M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.31M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$7.13M
EBITDA Margin
-4847.72%
TTM Avg
-2918.14%
3Y Avg
-1630.06%
5Y Avg
-1069.46%
Market Cap
$7.43M
EBITDA Margin
-1839.87%
TTM Avg
-1245.27%
3Y Avg
-1681.64%
5Y Avg
-1341.06%
Market Cap
$6.66M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.24M | 3.56% | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.28M | -2068.24% | -1510.83% | -1474.78% | -1474.78% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.29% | -74.83% | -125.41% | -344.12% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
| Longeveron Inc. (LGVN)vs › | $7.43M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.66M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.55M | -10.17% | -10.02% | -12.29% | -11.98% |
Gross Margin
0.0%
EBITDA Margin
3.6%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-12-31 | 3.56% |
